Increased Risk of High-Grade Hemorrhage in Cancer Patients Treated with Gemcitabine: A Meta-Analysis of 20 Randomized Controlled Trials

Yi Hu, Jingliang Wang, Haitao Tao, Baishou Wu, Jin Sun, Yao Cheng, Weiwei Dong, Ruixin Li

Department of Oncology, Chinese PLA General Hospital, Beijing City, People’s Republic of China

Abstract

Purpose: Gemcitabine, a third-generation anticancer agent, has been shown to be active in several solid tumors. High-grade hemorrhage (grade $\geq 3$) has been reported with this drug, although the overall risk remains unclear. We conducted a meta-analysis of randomized controlled trials evaluating the incidence and risk of high-grade hemorrhage associated with gemcitabine.

Methods: Pubmed was searched for articles published from January 1, 1990 to December 31, 2012. Eligible studies included prospective randomized controlled phase II and III trials evaluating gemcitabine-based vs non-gemcitabine-based therapy in patients with solid tumors. Data on high-grade hemorrhage were extracted. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of included trials.

Results: A total of 6433 patients from 20 trials were included. Among patients treated with gemcitabine-based chemotherapy, the overall incidence of high-grade hemorrhage was 1.7% (95%CI: 0.9–3.1%), and the RR of high-grade hemorrhage was 2.727 (95%CI: 1.581–4.702, $p<0.001$). Exploratory subgroup analysis revealed the highest RR of hemorrhage in non-small-cell lung cancer (NSCLC) patients (RR: 3.234; 95%CI, 1.678–6.233; $p<0.001$), phase II trials (RR 7.053, 95%CI: 1.591–31.27; $p=0.01$), trials reported during 2006–2012 (RR: 3.750; 95%CI: 1.735–8.108, $p<0.001$) and gemcitabine used as single agent (RR 7.48; 95%CI: 0.78–71.92, $p=0.081$).

Conclusion: Gemcitabine is associated with a significant increase risk of high-grade hemorrhage in patients with solid tumors when compared with non-gemcitabine-based therapy.

Introduction

High-grade hemorrhage is a significant cause of morbidity and mortality in patients with cancer [1,2,3,4]. Although the presence of malignancy itself and its associated physiologic changes are likely major contributors to an increased risk of hemorrhage, several cancer treatments, including targeted agents, cytotoxic agents, and supportive care medications [5,6,7,8,9], have also been associated with increased risk of hemorrhage. Since first approved in 1996 for the treatment of unresectable pancreatic carcinoma, gemcitabine, a widely used pyrimidine antimetabolite that interferes with DNA synthesis, has been shown to be active in other solid tumors [10,11,12,13,14,15,16,17]. Although common adverse events associated with gemcitabine are myelosuppression and mild liver function abnormalities [18], high-grade hemorrhage (grade $\geq 3$) has been sporadically reported in several randomized controlled trials (RCTs) [19,20,21,22,23,24,25]. However, the risk of high-grade bleeding in cancer patients receiving gemcitabine that has been reported in clinical trials has not been completely consistent, and none of these trials is large enough to define the overall risk. In addition, an individual trial may be limited to the study of one tumor type. Therefore, we propose that pooling analyses of the current studies may provide a better understanding of the overall risk of high-grade bleeding among cancer patients who receive gemcitabine. As a result, we performed a systematic review and meta-analysis of RCTs to evaluate the incidence and relative risk (RR) of high-grade hemorrhage in cancer patients receiving gemcitabine-based versus non-gemcitabine-based chemotherapy.

Methods

Data Source

The selection and systematic review of trials was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [26]. Trials were selected from those published in PubMed between January 1, 1990, and December 31, 2012, with “gemcitabine,” “cancer,” “carcinoma”, and “randomized clinical
trial” as keywords. Only trials published in peer-reviewed publications in full manuscript form in English were eligible. Only the most recent publication was included when duplicates were identified.

Study Selection
Our primary objective was to evaluate the association between treatment with gemcitabine-based therapy and high-grade hemorrhage in patients with cancer. Clinical trials meeting the following criteria were included in the meta-analysis: 1) prospective randomized controlled phase II or III trial of cancer patients, 2) random assignment of participants to treatment with gemcitabine or non-gemcitabine-containing therapy, and 3) available data on high-grade hemorrhage. The quality of reports of clinical trials was assessed and calculated using the 5-item Jadad scale including randomization, double-blinding, and withdrawals as previously described [27].

Data Extraction and Clinical End Point
Data extraction was conducted independently by two investigators (Y.H. and W.J.), and any discrepancy between the reviewers was resolved by consensus. For each study, the following information was extracted: author, publication year, trial phase, treatment arms, number of patients enrolled, number evaluable for toxicity, underlying malignancy, median age, median treatment duration, median progression-free survival, adverse outcomes of interest (high-grade hemorrhagic events), gemcitabine dosage (mg/m²). The following adverse outcomes were considered as hemorrhagic events and included in the main analysis: ecchymosis or petechiae; epistaxis; eye hemorrhage; gastrointestinal hemorrhage; gum hemorrhage; injection-site hemorrhage; hematemesis; hematuria; hemoptysis; non-specific hemorrhage; hemotherax; melena; menorrhagia; metrorrhagia; purpura; rectal hemorrhage; retroperitoneal hemorrhage; CNS hemorrhage; and vaginal hemorrhage (includes menorrhagia and metrorrhagia). We also included (when available) the incidences of high-grade (grade 3 or above) hemorrhagic events. We assessed and recorded adverse events according to the National Cancer Institute’s common toxicity criteria (version 2 or 3), which have been adopted widely in cancer clinical trials [28].

Statistical Analysis
All analyses were performed using Stata version 12.0 software (Stata Corporation, College Station, Texas, USA) and Open Meta-Analyst software version 4.16.12 (Tufts University, URL http://tuftscaes.org/open_meta/). For the calculation of incidence, the number of patients with high-grade hemorrhagic events and the number of patients receiving gemcitabine were extracted from the selected clinical trials; the proportion of patients with high-grade hemorrhagic events and 95% confidence interval (CI) were derived for each study. For the calculation of relative risk (RR), patients assigned to gemcitabine-based therapy were compared only with those assigned to control treatment in the same trial. Between-study heterogeneity was estimated using the \( \chi^2 \)-based Q statistic [29]. Heterogeneity was considered statistically significant when \( P_{\text{heterogeneity}} < 0.1 \). If heterogeneity existed, data was analyzed using a random effects model (DerSimonian Laird method). In the absence of heterogeneity, a fixed effects model was used (Mantel-Haenszel method). Continuity corrections with 0.5 were adopted for trials with zero events in either or both arms. A two-sided \( p \)-value less than 0.05 was considered significant. Prespecified subgroup analyses were performed according to tumor type, phase of trials, publication year or treatment regimens. To assess the stability of results, sensitivity analysis was performed by sequential omission of individual studies. The presence of publication bias was evaluated by using the Begg and Egger tests [30,31].

Results
Systematic Literature Search
The literature search yielded 1457 publications describing the use of gemcitabine, and 20 RCTs were finally included in the

Figure 1. Selection process for randomized controlled trials included in the meta-analysis.
doi:10.1371/journal.pone.0074872.g001
Table 1. Characteristics of 20 included trials in the meta-analysis (n = 6433).

| Studies | Phase | Underlying malignancies | Enrolled patients (n) | Treatment arms | Patients for analysis | Median age (years) | Median treatment duration (months/cycles) | Median PFS/TTP (months) | Median OS (months) | Jadad score | Reported bleeding events |
|---------|-------|-------------------------|-----------------------|----------------|----------------------|-------------------|-------------------------------------------|------------------------|------------------|-------------|--------------------------|
| Cardenal F. et al 1999 III NSCLC 135 | GEM 1250 mg/m²+CDDP q.3.w. | 69 | 69 | 4.1 | 6.9 | 8.7 | 2 | Hemothage |
| Crino L. et al 1999 III NSCLC 370 | VP-16+CDDP q.3.w. | 66 | 66 | 3.1 | 4.3 | 7.2 | |
| Sandler A.B. et al 2000 III NSCLC 522 | GEM 1000 mg/m²+CDDP q.4.w. | 152 | 152 | 4 cycles | 5.0 | 8.6 | 2 | Hemothage |
| Von der Maase H. et al 2000 III Bladder cancer 405 | CDDP q.4.w. | 203 | 203 | 5.8 | 13.8 | 2 | Hemothage |
| Sculier J.P. 2002 III NSCLC 284 | MVAC q.4.w. | 202 | 202 | NR | 4.6 | 14.8 | |
| Comella P et al. 2004 II NSCLC 264 | GEM 1200 mg/m² q.4.w. | 68 | 68 | NR | 3.3 | 5.1 | 3 | Bleeding |
| Feher O. et al 2005 III MBC 410 | GEM 1200 mg/m² q.4.w. | 198 | 198 | 3.5 cycles | 3.4 | 11.8 | 2 | Hemothage |
| Georgoulias V. et al 2005 III NSCLC 413 | EPI q.4.w. | 199 | 199 | 4.6 cycles | 6.1 | 19.1 | |
| Zielinski C. et al 2005 III MBC 259 | GEM 1000 mg/m²+EP+PTX q.3.w. | 130 | 130 | 7 cycles | 9.1 | 29.5 | 2 | Bleeding |
| Thomas P. et al 2006 II NSCLC 100 | FU+EP+CTX q.3.w. | 122 | 122 | 8 cycles | 9.0 | 24.9 | |
| Oettle H. et al 2007 III Pancreatic cancer 368 | GEM 1000 mg/m² q.4.w. | 186 | 186 | 6 cycles | 13.4 | 22.1 | 3 | Bleeding |
| Studies                  | Phase | Underlying malignancies | Enrolled patients (n) | Treatment arms | Patients for analysis | Median age (years) | Median treatment duration (months/cycles) | Median PFS/TTP (months) | Median OS (months) | Jadad score | Reported bleeding events |
|-------------------------|-------|-------------------------|-----------------------|----------------|----------------------|-------------------|------------------------------------------|------------------------|-------------------|-------------|--------------------------|
| **Ohe Y. et al 2007**   | III   | NSCLC                   | 602                   | GEM 1000 mg/m²+DDP q.3.w. | 151                | 61               | NR                                      | 3.2                    | 14.0              | 2           | Cerebral hemorrhage     |
|                         |       |                         |                       | PTX+CBP q.3.w.          | 148                | 63               | NR                                      | 3.2                    | 12.3              |             |                          |
|                         |       |                         |                       | CPT-11+DDP q.4.w.       | 147                | 62               | NR                                      | 3.3                    | 13.9              |             |                          |
|                         |       |                         |                       | NVB+DDP q.3.w.          | 146                | 61               | NR                                      | 3.0                    | 11.4              |             |                          |
| **Gronberg B.H. et al 2009** | III   | NSCLC                   | 436                   | GEM 1000 mg/m²+CBP q.3.w. | 217                | 66               | 3.1 cycles                               | NR                     | 7.0               | 2           | Bleeding                 |
|                         |       |                         |                       | PEM+CBP q.3.w.          | 219                | 64               | 3.3 cycles                               | NR                     | 7.3               |             |                          |
| **Ueno H. et al. 2009** | III   | Pancreatic cancer       | 119                   | Gemcitabine 1000 mg/m² q.4.w. | 57                | 65               | 3 cycles                                 | 11.4                   | 22.3              | 2           | GI bleeding              |
|                         |       |                         |                       | Observation             | 60                 | 64               | –                                        | 5.0                    | 18.4              |             |                          |
| **Hainsworth J.D. et al. 2010** | III   | Carcinoma of unknown primary site | 198                  | GEM 1000 mg/m²+CPT-11 q.3.w. | 105               | 59               | 4 cycles                                 | 5.3                    | 8.5               | 3           | Bleeding                 |
|                         |       |                         |                       | PTX+CBP+ VP-16 q.3.w.   | 93                 | 61               | 3 cycles                                 | 3.3                    | 7.4               |             |                          |
| **Treat J.A. et al 2010** | III   | NSCLC                   | 1135                  | GEM 1000 mg/m²+CBP q.3.w. | 356                | 64.1             | 4 cycles                                 | 4.3                    | 7.9               | 2           | Hemorrhage               |
|                         |       |                         |                       | GEM 1000 mg/m²+CBP q.3.w. | 355                | 64.3             | 4 cycles                                 | 4.5                    | 8.5               |             |                          |
|                         |       |                         |                       | PTX+CBP q.3.w.          | 366                | 64.1             | 4 cycles                                 | 4.7                    | 8.7               |             |                          |
| **Brufsky A. et al 2011** | II    | MBC                     | 191                   | GEM 1500 mg/m²+PTX +BEV q.4.w. | 93                 | 55.2             | 6 cycles                                 | 11.3                   | 24.3              | 3           | Epistaxis, hemorrhage    |
|                         |       |                         |                       | PTX+BEV q.4.w.          | 94                 | 57.5             | 6 cycles                                 | 8.8                    | 25.0              |             |                          |
| **Gridilli C. et al 2011** | II    | NSCLC                   | 60                    | GEM 1200 mg/m²+SOR q.3.w. | 31                 | 74               | NR                                      | 8.1 weeks              | 6.6               | 2           | Pulmonary hemorrhage, bleeding |
|                         |       |                         |                       | SOR+ erlotinib         | 29                 | 76               | NR                                      | 12.7 weeks              | 12.6              |             |                          |
| **El-Khoueiry A.B. et al 2012** | II    | Pancreatic cancer       | 52                    | GEM 1000 mg/m²+SOR q.3.w. | 37                 | 65               | 2 cycles                                 | 2.9                    | 6.5               | 2           | GI bleeding              |
|                         |       |                         |                       | SOR                    | 15                 | 66               | 2 cycles                                 | 2.3                    | 4.3               |             |                          |
| **Spigel D.R. et al 2012** | II    | NSCLC                   | 110                   | GEM 1500 mg/m²+PEM +BEV q.4.w. | 55                 | 76               | 2.5 cycles                               | 4.7                    | 7.5               | 2           | Pulmonary hemorrhage     |
|                         |       |                         |                       | PEM+CBP+BEV q.3.w.      | 55                 | 77               | 6 cycles                                 | 10.2                   | 14.8              |             |                          |

Abbreviation: GEM, gemcitabine; CDDP, cisplatin; VP-16, etoposide; DOC, docetaxel; MIC, Mitomycin+IFO+cisplatin; MVAC, methotrexate+vinblastine+doxorubicin+cisplatin; CBP, carboplatin; IFO, ifosfamide; EPI, epirubicin; NVB, vinorelbine; PTX, paclitaxel; FU, fluorouracil; CTX, cyclophosphamide; PEM, pemetrexed; CPT-11, irinotecan; BEV, bevacizumab; SOR, sorafenib; GI, gastrointestinal tract; NSCLC, non-small-cell lung cancer; MBC, metastatic breast cancer; PFS, progression-free survival; TTP, time-to progression; OS, overall survival; NR, not reported; doi:10.1371/journal.pone.0074872.t001
meta-analysis. The selection process is summarized in Figure 1. In total, 6,433 patients were investigated in these trials and they had a variety of cancers: NSCLC (twelve trials) [19,20,23,32,33,34,35, 36,37,38,39,40], breast cancer (three trials) [24,41,42], pancreatic cancer (three trials) [13,43,44], bladder cancer (one trial) [21], Carcinoma of unknown (one trial) [45]. All included trials involved randomized treatment allocation. None were placebo controlled or double blind, and the median Jadad score was 2 (range = 2–3). Sample size were in the range of 50 to 1135 patients, with seven trials including >400 patients each. According to the inclusion criteria of each trial, patients were required to have an adequate renal, hepatic and hematologic function. The median age of study participants was in the range of 53–77 years (some studies only reported the mean age). Table 1 reports the study and patient characteristics for the included trials.

Publication Bias
No evidence of publication bias was detected for the RR of high-grade hemorrhagic events in this study by either Begg or Egger’s test (Begg’s test \( p = 0.81 \); Egger’s test \( p = 0.21 \)).

Incidence of High-grade Hemorrhage
A total of 6433 patients were included in the analysis. In the gemcitabine group, 53 patients experienced high-grade hemorrhage compared with 18 patients in the non-gemcitabine group. The highest incidence (23.5%; 95% CI, 13.9%–37.0%) as observed in a phase II NSCLC trial [35], and the lowest incidence was observed in five trials in which no hemorrhagic events occurred [23,33,34,36,42]. Using a random-effects model (heterogeneity test: \( Q = 81.314; P < 0.001; I^2 = 77% \)), the summary incidence of high-grade hemorrhagic events in patients receiving gemcitabine-based therapy was 1.7% (95% CI, 0.9%–3.1%, Figure 2).

Relative Risk of High-grade Hemorrhage
To investigate the specific contribution of gemcitabine to the development of hemorrhagic events and exclude the influence of confounding factors such as underlying malignancy, and other therapeutic interventions, we therefore determined the relative risk (RR) of gemcitabine associated hemorrhagic events. The combined results demonstrated that the use of gemcitabine was associated with a significantly increased risk of developing high-grade hemorrhage with a RR of 2.727 (95%CI: 1.581–4.702, \( p < 0.001 \), Figure 3). We also did sensitivity analysis to examine the stability and reliability of pooled RRs by sequential omission of individual studies. The results indicated that the significance estimate of pooled RRs was not significantly influenced by omitting any single study (Figure 4).

Influence of Underlying Tumor Type on RR of High-grade Hemorrhage
To better determine possible relationships between gemcitabine and high-grade hemorrhage, we performed several prespecified subgroup analyses, stratifying patients by malignancy, phase of trial and year of publication (Table 2). The incidence of severe hemorrhage was highest among patients with NSCLC (2.0%, 95%CI: 0.8–4.6%), followed by pancreatic cancer (1.4%, 95%CI: 0.4–4.1%) and MBC (1.0%, 95%CI: 0.3–2.7%). The effect sizes varied, and the highest RR of hemorrhage was observed in non-small-cell lung cancer patients (RR: 3.234; 95%CI, 1.678–6.233; \( p < 0.001 \), but the differences among tumor types were not statistically significant.

Influence of Phase of Trials on RR of High-grade Hemorrhage
Given the potentially differing risks of hemorrhage between phase II and III trials, an exploratory analysis stratifying patients by phase of trial was performed (Table 2). Interestingly, the effect

Figure 2. Incidence of high-grade hemorrhagic events associated with gemcitabine.
doi:10.1371/journal.pone.0074872.g002
size was greater in the phase II trials (RR 7.053, 95%CI: 1.591–31.27) versus phase III trials (RR 2.211, 95%CI: 1.211–4.038). However, there was no significant difference between these subgroups.

Influence of Publication Year on RR of High-grade Hemorrhage

We hypothesized that the incidence of severe hemorrhage reported in cancer clinical trials may have increased over the past decade. Therefore, we explored the impact of publication year on incidence and RR of severe hemorrhage with gemcitabine-based therapy. The results are depicted in Figure 3 and Figure 4.
Table 2. Relative risk of high-grade hemorrhage based on prespecified subgroups.

| Group                     | No. of trials | Gemcitabine arm | Non-gemcitabine arm | t², % | Relative risk (95%CI) | P for relative risk | P for group difference |
|---------------------------|---------------|-----------------|---------------------|-------|------------------------|---------------------|------------------------|
|                           |               | No. of events   | No. of patients     | Incidence (%) | No. of events | No. of patients | Incidence (%) |               |                        |                      |
|                           | 20            | 53              | 3227                | 1.7    | 18                     | 3014                | 1.2          | 0%             | 2.272 (1.581–4.702) | <0.001               | NA                    |
| Tumor type                |               |                 |                     |        |                        |                     |              |                |                           |                      |
| NSCLC                     | 12            | 12              | 2218                | 2.0    | 12                     | 2047                | 1.0          | 20%            | 3.234 (1.678–6.233) | <0.001               | 0.444                 |
| Pancreas                  | 3             | 3               | 280                 | 1.4    | 0                      | 257                 | 0.0          | 0%             | 2.259 (0.362–14.12)  | 0.383                 |                      |
| MBC                       | 3             | 3               | 421                 | 1.0    | 1                      | 415                 | 0.6          | 0%             | 2.955 (0.299–29.24)  | 0.354                 |                      |
| Others                    | 2             | 5               | 308                 | 1.7    | 5                      | 295                 | 1.8          | 0%             | 0.972 (0.285–3.321)  | 0.964                 |                      |
| Phase of trials           |               |                 |                     |        |                        |                     |              |                |                           |                      |
| Phase II                  | 6             | 15              | 403                 | 2.6    | 2                      | 370                 | 1.4          | 43%            | 7.053 (1.591–31.27)  | 0.01                  | 0.524                 |
| Phase III                 | 14            | 38              | 2824                | 1.6    | 16                     | 2644                | 0.9          | 0%             | 2.211 (1.211–4.038)  | 0.01                  |                      |
| Publication year          |               |                 |                     |        |                        |                     |              |                |                           |                      |
| 1999–2005                 | 9             | 17              | 1531                | 1.6    | 9                      | 1413                | 1.0          | 0%             | 1.808 (0.806–4.057)  | 0.151                 | 0.278                 |
| 2006–2012                 | 11            | 36              | 1696                | 2.1    | 9                      | 1601                | 1.2          | 0%             | 3.750 (1.735–8.108)  | <0.001                |                      |
| Gemcitabine-based regimens |               |                 |                     |        |                        |                     |              |                |                           |                      |
| Single agent              | 4             | 3               | 509                 | 0.8    | 0                      | 504                 | 0            | 0%             | 7.48 (0.78–71.92)    | 0.081                 | 0.876                 |
| Doublet combination       | 14            | 47              | 2413                | 2.0    | 17                     | 2237                | 1.3          | 8%             | 2.41 (1.45–3.99)     | <0.001                |                      |
| Triplet combination       | 4             | 3               | 370                 | 1.2    | 2                      | 365                 | 0.9          | 0%             | 1.47 (0.25–8.47)     | 0.67                  |                      |

Abbreviation: NSCLC, non-small-cell lung cancer; MBC, metastatic breast cancer; gemcitabine is used as single agent and combination therapy in two clinical trials, thus there is a total of 22 comparisons.
doi:10.1371/journal.pone.0074872.t002
therapy. Notably, the incidence of hemorrhage in the 9 trials published from 1999 to 2005 was 2.1% (95%CI: 0.9–5.4%), compared with an incidence of 1.6% (95%CI: 0.9–2.6%) in the 11 trials published from 2006 to 2012. In the 11 trials published from 2005 to 2012, gemcitabine-based therapy was associated with an RR of hemorrhage of 1.75 (95%CI: 1.73–8.108). In trials published from 1999 to 2005, gemcitabine-based therapy was associated with an RR of hemorrhage of 1.808 (95%CI: 0.806–4.057). This difference did not reach statistical significance.

Influence of Treatment Regimes on RR of High-grade Hemorrhage

Concomitant agents with gemcitabine, including bevacizumab and sorafenib, might increase the risk of gemcitabine-related hemorrhage events. We therefore performed sub-group analysis according to gemcitabine-based regimens. An increased risk of hemorrhage events was observed in gemcitabine used as single agent (RR 7.48, 95%CI: 0.78–71.92), doublet combination (RR 2.41, 95%CI: 1.35–3.99) and triplet combination (RR 1.47, 95%CI: 0.25–8.47) when compared to controls, though the risk did not significantly increase in gemcitabine therapy used as single agent (p = 0.081) and triplet combination (p = 0.67) (Table 2). One possible explanation for this finding was that there were a limited number of trials to investigate the risk of hemorrhage events in gemcitabine used as single agent and triplet combination, thus the power to investigate the risk was small. Interestingly, the effect size was greater in gemcitabine used as single agent versus gemcitabine combination, which suggested that concomitant agents with gemcitabine had limited effects on the risk of gemcitabine-related hemorrhage events.

Discussion

To our best knowledge, this is the first meta-analysis to investigate the risk of high-grade hemorrhage associated with gemcitabine. Our analysis of data from randomized controlled trials shows a nearly three-times increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine-based therapy. Additionally, the overall incidence of gemcitabine associated high-grade hemorrhagic events is 1.7% (95% CI, 0.9–3.1%). Based on these results, we could conclude that while the incidence of high-grade hemorrhage in patients treated with gemcitabine is low, the use of gemcitabine is associated with significantly increased risk of high-grade hemorrhage when compared with non-gemcitabine-based therapy. These results would provide important information for clinicians who use gemcitabine to treat patients with solid cancer.

Many factors such as age, race, sex, mobility, underlying cancer, and concurrent use of anticoagulants or chemotherapy are known to contribute to the development of hemorrhage in cancer patients [46]. Thus, we also explore the risk factors for gemcitabine associated hemorrhagic events. Our exploratory subgroup analyses reveal some interesting hypothesis-generating findings. The effect sizes vary with regard to the RR of hemorrhage in specific tumor types, and the highest RR of serious hemorrhage is observed in non-small-cell lung cancer patients (RR: 3.234; 95%CI, 1.678–6.233; p < 0.001). However, the interpretation of these findings is hampered by the low number of patients and events in certain subgroups. As a result, more high-quality trials are still needed to investigate the risk of gemcitabine associated hemorrhage in these tumors. We hypothesize that the incidence of serious hemorrhage reported in clinical trials over the last decade may have increased because of an increased awareness that serious hemorrhage may be treatment rather than disease related. Indeed, the incidence of serious hemorrhage is higher in trials published between 2006 and 2012 compared with trials published between 1999 and 2005. Then, we also investigate the differing risks of hemorrhage between phase II and III trials. Interestingly, the effect size is greater in the phase II trials versus phase III trials. However, there is no significant difference between these subgroups. Finally, we perform sub-group analysis to detect the influence of concomitant agents on risk of hemorrhage, and find that there is an increased risk of hemorrhage events in gemcitabine used as single agent, doublet combination and triplet combination when compared to controls, though the risk did not significantly increase in gemcitabine therapy used as single agent and triplet combination.

The pathogenesis of gemcitabine-induced hemorrhage remains unclear, gemcitabine-induced thrombocytopenia may be directly related to its increased risk of hemorrhage, but the risk of hemorrhage depends not only the platelet count, but also on the underlying disease, platelet function and complications such as fever and infection or the presence of coagulation defects [47]. It is unknown whether gemcitabine affects the coagulation cascade or endothelial cell. As a result, studies focusing on this issue are still needed.

Our meta-analysis had several limitations. First, this meta-analysis was not based on individual patient data, and meta-analyses based on published data tends to overestimate treatment effects compared with individual patient data analyses. In addition, it precluded a more comprehensive analysis such as adjusting for baseline factors and other differences that existed between the trials from which the data were pooled. Therefore, the results must be interpreted cautiously, as an individual patient data-based meta-analysis would give more reliable estimation than one based on published data. Secondly, trials reported zero high-grade hemorrhage in one or both arms were also included for analysis. In this setting, using fixed effects models and continuity corrections would bias the results towards null. But we felt that including trials reporting zero high-grade hemorrhage would provide the most conservative estimate. Thirdly, different treatment strategy, duration, and regimens contributed to increase the clinical heterogeneity of the meta-analysis, which made the interpretation of the meta-analysis more problematic, although we performed sub-group analysis and sensitive analysis. Additionally, targeted drugs including bevacizumab [7,9] and sorafenib [8], could increased the risk of hemorrhage, which is another potential bias for evaluating the risk of hemorrhage by gemcitabine.

In conclusion, although the incidence of high-grade hemorrhage in patients treated with gemcitabine is low, a significantly increased risk of high-grade hemorrhage is detected when compared with non-gemcitabine therapy. Clinicians should be cautious when using gemcitabine-based therapy for treating cancer patients, especially those at high risk.

Supporting Information

Checklist S1 PRISMA Checklist.

(DOC)

Author Contributions

Conceived and designed the experiments: YH JW HT. Performed the experiments: BW JS YC. Analyzed the data: WD RL. Contributed reagents/materials/analysis tools: YH JW. Wrote the paper: YH WD RL.
References

1. Pavarone A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ (1998) Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol 21: 381.

2. Cerny CL, Cournia L, Cupi T, Belle E, Pernet D, et al. (2001) Gemcitabine-associated diffuse alveolar hemorrhage. Intensive Care Med 27: 1554.

3. Nicholls L, Saunders R, Knollmann FD (2012) Causes of death of patients with lung cancer. Arch Pathol Lab Med 136: 1552–1557.

4. Chait MM, Turnbull AD, Winson SJ (1979) Risk factors and mortality in patients with cancer and hemorrhage from stercoraceous tumors. Am J Gastroenterol 72: 227–233.

5. Blitt LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, et al. (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19: 1137–1146.

6. Levine MN, Raskob G, Landefeld S, Kearon C (2001) Hemorrhagic complications of anticoagulant treatment. Chest 119: 1085–1218.

7. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79: 27–38.

8. Yr Y, Schutz FA, Choussy TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sutentin and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10: 967–974.

9. Hang XF, Xu WS, Wang JX, Wang L, Xin HG, et al. (2011) Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 67: 613–623.

10. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413.

11. Frasci G, Cornella P, D’Anto G, Thomas R, Capasso I, et al. (2000) Gemcitabine plus cisplatin or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 11: 367–371.

12. Cunic S, Lortholary A, Voigt JJ, Bugat R, Theodore C, et al. (2005) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study: study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAP 01). J Clin Oncol 23: 3479–3482.

13. Oettle H, Post S, Neuhau P, Gellert K, Langreb KJ, et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267–277.

14. De Santis M, Bellmunt J, Mead G, Krst JM, Leahy M, et al. (2009) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “ unfit” for cisplatin-based chemotherapy: phase II results of EORTC study 30986. J Clin Oncol 27: 5634–5639.

15. Addo S, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, et al. (2010) Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28: 5470–5478.

16. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, et al. (2010) Gemcitabine, eribulin, and paclitaxel versus paclitaxel alone for elderly or unfit advanced non-small-cell lung cancer. J Clin Oncol 28: 4158–4167.

17. Cabrera A, Catalano P, Carvalho NV, Jr, et al. (2005) Gemcitabine plus paclitaxel by 4-weekly cycles or every 3 weeks for patients with locally advanced or metastatic non-small-cell lung cancer: a randomized phase II trial. J Clin Oncol 23: 2937–2945.

18. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, et al. (2001) Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19: 1137–1146.

19. Levine MN, Raskob G, Landefeld S, Kearon C (2001) Hemorrhagic complications of anticoagulant treatment. Chest 119: 1085–1218.

20. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79: 27–38.

21. NCI, Cancer Therapy Program. CTC v 2.0 and common terminology criteria for adverse events criteria V 3.0 (CTCAE). Available: http://ctepcancer.gov/protocolDevelopment/electronic_applications/ctctrm. Accessed 2013 Jan 27.

22. Zuzov Z, Leandina JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123–137.

23. Yunci S, Petes R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335–370.

24. Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, et al. (2005) First-line pemetrexed/gemcitabine/bevacizumab compared with cisplatin plus bevacizumab in patients with advanced non-small-cell lung cancer: the MILES-2P studies. J Clin Oncol 25: 4663–4669.

25. Gridelli C, Maione P, Illiano A, Piantedosi FV, Favaretto A, et al. (2007) Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small-cell lung cancer: the MILES-2P studies. J Clin Oncol 25: 4663–4669.

26. Moher DL, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.

27. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609–613.

28. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609–613.

29. Gejmanov P, Bokarewa M, Massidda B, Buzzi F, et al. (2004) Gemcitabine with other paclitaxel or vinorelbine as paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91: 498–497.

30. Thomas P, Robinet G, Gouva S, Fournel P, Lena H, et al. (2006) Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small-cell lung cancer patients with chemotherapy-induced thrombocytopenia. Oncology 79: 27–38.

31. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.

32. Pao ARS LG, Biemta B, Heigener D, von Pawel J, Eisen T, et al. (2012) Phase III randomized phase III trial comparing gemcitabine/cisplatin versus gemcitabine and sorafenib in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17: 12–18.

33. Sculier JP, Luffte J, Leconte J, Berghmans T, Thiriaux J, et al. (2002) A three-arm phase III randomized trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 13: 874–882.

34. Cornella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, et al. (2004) Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91: 498–497.

35. Thomas P, Robinet G, Gouva S, Fournel P, Lena H, et al. (2006) Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small-cell lung cancer patients with chemotherapy-induced thrombocytopenia. Oncology 79: 27–38.

36. Costantini M, Kasperkiewicz H, Saldana R, et al. (2010) gemcitabine in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study. Br J Cancer 102: 1227–1231.

37. Cabrera A, Catalano P, Carvalho NV, Jr, et al. (2005) Gemcitabine plus paclitaxel by 4-weekly cycles or every 3 weeks for patients with locally advanced or metastatic non-small-cell lung cancer: a randomized phase II trial. J Clin Oncol 23: 2937–2945.
phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 16: 70–75.

46. Gorter JW (1999) Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT), European Atrial Fibrillation Trial (EAFT) study groups. Neurology 53: 1319–1327.

47. Avvisati G, Tirindelli MC, Annibali O (2003) Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol 48: S13–16.